SCHEMBL2392888

SCHEMBL2392888

CCOC(=O)C(C)c1ccccc1-c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.46
PIN1 Q13526 1/20 0.45
TDP1 Q9NUW8 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
NPC1 O15118 1/20 0.44
PTPN1 P18031 1/20 0.44
PPARA Q07869 2/20 0.43
PPARG P37231 1/20 0.43
TSHR P16473 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.42
MAPT P10636 2/20 0.42
PRNP P04156 1/20 0.42
MMP8 P22894 1/20 0.42
ALDH1A1 P00352 2/20 0.42
SCN1A P35498 1/20 0.42
SCN2A Q99250 1/20 0.42
SCN3A Q9NY46 1/20 0.42
KDM4E B2RXH2 1/20 0.42
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30677889 0.89 CA12 (0.42) LMNAPIN1TDP1MEN1KMT2A
SCHEMBL10914468 0.86 PPARA (0.42) LMNAMEN1KMT2APPARAPPARG
SCHEMBL10710439 0.83 KMT2A (0.46) LMNAKMT2APPARAPPARGMAPT
SCHEMBL363983 0.81 TSHR (0.48) LMNAPIN1TDP1MEN1KMT2A
SCHEMBL21715127 0.81 PTGS2 (0.43) LMNAPPARAPPARGTSHRMMP8
SCHEMBL7171639 0.80 LMNA (0.43) LMNAPIN1MEN1KMT2ANPC1
SCHEMBL4536517 0.80 LMNA (0.40) LMNAPIN1MEN1KMT2ANPC1
SCHEMBL28008252 0.80 NLRP3 (0.50) LMNAPIN1TDP1MEN1KMT2A
SCHEMBL2393839 0.79 PTGS2 (0.56) LMNAMEN1KMT2APPARAPPARG
SCHEMBL8486754 0.79 KMT2A (0.44) KMT2APPARAPPARGALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
CN-102282124-A Biphenylacetamide derivative 2011-12-14 CN disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 LMNA 3980/4885PIN1 3532/4885TDP1 4273/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 LMNA 3980/4885PIN1 3532/4885TDP1 4273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.